Finally, we found for the first time that shRNA-mediated repression of DNAJC19 greatly attenuated tumor cell growth and intrapulmonary metastasis by regulating PI3K/AKT, highlighting DNAJC19 as a novel therapeutic target for treating NSCLC patients. The gene discussed is PIK3CA; the disease is neoplasm.